CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2- Breast Cancer.

Benn CA, Banda A, Waja F, van Loggerenberg D, Van Loggerenberg C

Open source

DOI
10.6004/jnccn.2025.7291
Published
2026 Mar 31
Container
Journal of the National Comprehensive Cancer Network : JNCCN
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.6004/jnccn.2025.7291,
  title = {CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2- Breast Cancer.},
  author = {Benn CA and Banda A and Waja F and van Loggerenberg D and Van Loggerenberg C},
  year = {2026},
  journal = {Journal of the National Comprehensive Cancer Network : JNCCN},
  doi = {10.6004/jnccn.2025.7291},
  url = {https://doi.org/10.6004/jnccn.2025.7291}
}

RIS

TY  - JOUR
TI  - CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2- Breast Cancer.
AU  - Benn CA
AU  - Banda A
AU  - Waja F
AU  - van Loggerenberg D
AU  - Van Loggerenberg C
PY  - 2026
JO  - Journal of the National Comprehensive Cancer Network : JNCCN
DO  - 10.6004/jnccn.2025.7291
UR  - https://doi.org/10.6004/jnccn.2025.7291
ER  - 

APA

CA, B., A, B., F, W., D, V. L., & C, V. L. (2026). CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2- Breast Cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. https://doi.org/10.6004/jnccn.2025.7291

Source records